BMJ Article Questions the Use of Surrogate Endpoints in Drug Assessments

September 20, 2021

An article published in the British Medical Journal (BMJ) details the controversial use of surrogate endpoints in assessing a drug’s efficacy, such as in the recent approval of Biogen’s Aduhelm. The use of surrogate endpoints does not always indicate that a drug is successful; some approved drugs have later been recalled.

According to the authors, “We argue for more selective use of surrogate endpoints when evaluating new drugs, restricting their use to chronic diseases, especially when collecting data on patient relevant clinical outcomes requires trials with unattainably long follow up.” Read the article here.

(Source: Dawoud et al., The British Medical Journal, 2021)

Share This Story!